Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies

dc.contributor.authorChan X.H.S.
dc.contributor.authorChotsiri P.
dc.contributor.authorCapel R.A.
dc.contributor.authorPike J.
dc.contributor.authorHanboonkunupakarn B.
dc.contributor.authorLee S.J.
dc.contributor.authorHanafiah M.
dc.contributor.authorWin Y.N.
dc.contributor.authorCremer M.A.
dc.contributor.authorKiechel J.R.
dc.contributor.authorOgutu B.
dc.contributor.authorTaylor W.R.J.
dc.contributor.authorBurton R.A.B.
dc.contributor.authorTarning J.
dc.contributor.authorWhite N.J.
dc.contributor.otherMahidol University
dc.date.accessioned2023-05-19T07:53:52Z
dc.date.available2023-05-19T07:53:52Z
dc.date.issued2023-03-01
dc.description.abstractAims: Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized. Methods: We conducted a secondary analysis of a pharmacokinetic study of the cardiac safety of amodiaquine (10 mg base/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Nonlinear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration–effect relationships for vital sign (pulse rate, blood pressure) and electrocardiograph interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. Results: Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% confidence interval: 1.5–2.4), supine systolic blood pressure (1.7 mmHg per 100 nmol/L; 1.2–2.1), erect systolic blood pressure (1.5 mmHg per 100 nmol/L; 1.0–2.0) and erect diastolic blood pressure (1.4 mmHg per 100 nmol/L; 1.0–1.7). The mean QT interval prolongation was 1.4 ms per 100 nmol/L irrespective of correction factor after adjustment for residual heart rate dependency. There was no significant effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n = 6) and desethylamodiaquine (n = 8) at 3 μmol/L (amodiaquine: 10 ± 2%; desethylamodiaquine: 12 ± 3%) and 10 μmol/L (amodiaquine: 50 ± 7%; desethylamodiaquine: 46 ± 6%) concentrations with no significant difference in potency between the 2 compounds. Conclusion: Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarization.
dc.identifier.citationBritish Journal of Clinical Pharmacology Vol.89 No.3 (2023) , 1176-1186
dc.identifier.doi10.1111/bcp.15569
dc.identifier.eissn13652125
dc.identifier.issn03065251
dc.identifier.pmid36256474
dc.identifier.scopus2-s2.0-85141481333
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/82209
dc.rights.holderSCOPUS
dc.subjectPharmacology, Toxicology and Pharmaceutics
dc.titleCardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85141481333&origin=inward
oaire.citation.endPage1186
oaire.citation.issue3
oaire.citation.startPage1176
oaire.citation.titleBritish Journal of Clinical Pharmacology
oaire.citation.volume89
oairecerif.author.affiliationFaculty of Tropical Medicine, Mahidol University
oairecerif.author.affiliationMahidol Oxford Tropical Medicine Research Unit
oairecerif.author.affiliationKenya Medical Research Institute
oairecerif.author.affiliationNuffield Department of Medicine
oairecerif.author.affiliationUniversity of Oxford Medical Sciences Division
oairecerif.author.affiliationUniversity of Medicine
oairecerif.author.affiliationDrugs for Neglected Diseases Initiative

Files

Collections